CTSA Visiting Scholar Program: Tolerable Strategies to Overcome Treatment Resistance in Breast Cancer

NIH National Center for Advancing Translational Sciences

KL2 awardees from Clinical and Translational Science Centers (CTSA) present virtual lectures as part of the CTSA Visiting Scholar Program.

Mathew Cherian MD, from Ohio State University, hosted by the National Center for Advancing Translational Sciences will present his research on "Tolerable Strategies to Overcome Treatment Resistance in Breast Cancer"

Resistance to first-line endocrine and cyclin-dependent kinase 4/6 inhibitors, the greatest challenge in the management of estrogen receptor α positive breast cancer today, is mediated by diverse and intersecting signaling pathways, precluding the development of therapies that target a single resistance factor. The activation of a second estrogen receptor, estrogen receptor β, leads to the transcriptional upregulation of multiple tumor suppressor pathways and our data shows that a highly selective estrogen receptor β agonist, which was invented at our institution, counters endocrine and cyclin-dependent kinase 4/6 inhibitor resistance in vitro. We propose a novel therapeutic strategy that will reactivate estrogen receptor β to concurrently counter multiple mechanisms of endocrine and cyclin-dependent kinase 4/6 resistance in breast cancer.

Dr. Cherian is an assistant professor in medical oncology, Breast Section, at The Ohio State University Comprehensive Cancer Center in Columbus, Ohio. He runs a basic research laboratory focused on the cancer biology of breast cancer. His clinical practice is focused on the care of breast cancer of all stages at the Stephanie Spielman Comprehensive Breast Center and the James Cancer Hospital, also in Columbus, Ohio.

Date
- Add to Calendar 2021-04-23 17:00:00 2021-04-23 18:00:00 CTSA Visiting Scholar Program: Tolerable Strategies to Overcome Treatment Resistance in Breast Cancer Register Here https://nih.webex.com/nih/onstage/g.php?MTID=ec2a2b64d738840733ecba259c45ae17e

KL2 awardees from Clinical and Translational Science Centers (CTSA) present virtual lectures as part of the CTSA Visiting Scholar Program.

Mathew Cherian MD, from Ohio State University, hosted by the National Center for Advancing Translational Sciences will present his research on "Tolerable Strategies to Overcome Treatment Resistance in Breast Cancer"

Resistance to first-line endocrine and cyclin-dependent kinase 4/6 inhibitors, the greatest challenge in the management of estrogen receptor α positive breast cancer today, is mediated by diverse and intersecting signaling pathways, precluding the development of therapies that target a single resistance factor. The activation of a second estrogen receptor, estrogen receptor β, leads to the transcriptional upregulation of multiple tumor suppressor pathways and our data shows that a highly selective estrogen receptor β agonist, which was invented at our institution, counters endocrine and cyclin-dependent kinase 4/6 inhibitor resistance in vitro. We propose a novel therapeutic strategy that will reactivate estrogen receptor β to concurrently counter multiple mechanisms of endocrine and cyclin-dependent kinase 4/6 resistance in breast cancer.

Dr. Cherian is an assistant professor in medical oncology, Breast Section, at The Ohio State University Comprehensive Cancer Center in Columbus, Ohio. He runs a basic research laboratory focused on the cancer biology of breast cancer. His clinical practice is focused on the care of breast cancer of all stages at the Stephanie Spielman Comprehensive Breast Center and the James Cancer Hospital, also in Columbus, Ohio.

https://staging2.clic-ctsa.org/events/ctsa-visiting-scholar-program-tolerable-strategies-overcome-treatment-resistance-breast NCATS admin@clic-ctsa.org America/New_York public
Activity Type
Educational Offering
Organization
Location Type
Online
Register Here